Success Metrics

Clinical Success Rate
50.0%

Based on 2 completed trials

Completion Rate
50%(2/4)
Active Trials
1(17%)
Results Posted
0%(0 trials)
Terminated
2(33%)

Phase Distribution

Ph phase_3
1
17%
Ph phase_2
4
67%
Ph phase_1
1
17%

Phase Distribution

1

Early Stage

4

Mid Stage

1

Late Stage

Phase Distribution6 total trials
Phase 1Safety & dosage
1(16.7%)
Phase 2Efficacy & side effects
4(66.7%)
Phase 3Large-scale testing
1(16.7%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

50.0%

2 of 4 finished

Non-Completion Rate

50.0%

2 ended early

Currently Active

1

trials recruiting

Total Trials

6

all time

Status Distribution
Active(2)
Completed(2)
Terminated(2)

Detailed Status

Terminated2
Completed2
Not yet recruiting1
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
1
Success Rate
50.0%
Most Advanced
Phase 3

Trials by Phase

Phase 11 (16.7%)
Phase 24 (66.7%)
Phase 31 (16.7%)

Trials by Status

not_yet_recruiting117%
terminated233%
recruiting117%
completed233%

Recent Activity

1 active trials
Showing 5 of 6
completedphase_1

A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of AK120 in Subjects With Atopic Dermatitis

NCT06035354
terminatedphase_2

Phase 2 Study of Efficacy and Safety of AK120, in Subjects With Moderate-to-Severe Atopic Dermatitis

NCT05048056
not_yet_recruitingphase_2

A Clinical Study of AK120 in Adolescents With Moderate-to-severe Atopic Dermatitis (AD)

NCT06756126
completedphase_2

A Study to Evaluate the Safety and Efficacy of AK120 in Subjects With Moderate to Severe Atopic Dermatitis

NCT06092762
recruitingphase_3

A Phase III Study to Evaluate the Efficacy and Safety of AK120 in Patients With Moderate to Severe Atopic Dermatitis

NCT06383468
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT06035354Phase 1

A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of AK120 in Subjects With Atopic Dermatitis

Completed
NCT05048056Phase 2

Phase 2 Study of Efficacy and Safety of AK120, in Subjects With Moderate-to-Severe Atopic Dermatitis

Terminated
NCT06756126Phase 2

A Clinical Study of AK120 in Adolescents With Moderate-to-severe Atopic Dermatitis (AD)

Not Yet Recruiting
NCT06092762Phase 2

A Study to Evaluate the Safety and Efficacy of AK120 in Subjects With Moderate to Severe Atopic Dermatitis

Completed
NCT06383468Phase 3

A Phase III Study to Evaluate the Efficacy and Safety of AK120 in Patients With Moderate to Severe Atopic Dermatitis

Recruiting
NCT05155020Phase 2

A Study to Evaluate the Efficacy and Safety of AK120 in the Treatment of Subjects With Moderate-to-severe Asthma

Terminated

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6